Takeda announces first-quarter fy2025 results with significant late-stage pipeline progression

Osaka, japan--(business wire)--takeda (tokyo:4502/nyse:tak) today announced earnings results for the first quarter of fiscal year 2025 (three months ended june 30, 2025), with generic erosion of vyvanse significantly impacting revenue and core operating profit in line with company expectations for the quarter. the company expects these impacts to moderate in future quarters. takeda also achieved several important milestones in its r&d pipeline, reinforcing its long-term growth trajectory an.
TAK Ratings Summary
TAK Quant Ranking